What is PBLS's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 3.39B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for PBLS?

P/E (TTM) is n/a and 52-week range is $24.51 to $42.48 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s PBLS figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for PBLS?

The company profile lists net income (TTM) near $-238M, EPS (TTM) near $-2.04 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Parabilis Medicines Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Cambridge, Massachusetts, US, 116.6M shares outstanding, ISIN US6989551014 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Parabilis Medicines Inc

$PBLS

Health Care · Biotechnology

Run Scenarios

$27.48

-2.17%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Parabilis Medicines Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Cambridge, Massachusetts and currently employs 145 full-time employees. The company went IPO on 2026-06-10. Parabilis Medicines, Inc., formerly FOG Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The company is built to develop transformative medicines addressing undruggable protein targets driving human disease. The company leverages a proprietary platform to a novel therapeutic modality, Helicons, which are stabilized helical peptides engineered to bind and precisely modulate proteins that reach conventional medicine. Its lead product candidate, zolucatetide, is the first and only investigational therapy that inhibits the b-catenin: TCF interaction, the critical downstream node of the Wnt/b-catenin pathway. Its preclinical pipeline provides Helicon approach and includes programs targeting two key drivers of prostate cancer, the ETS-related gene and the androgen receptor (AR) in its active state (ARON). Helicon discovery platform integrates advanced AI and physics-based computational modeling with peptide synthesis and experimental screening to discover and develop drug candidates.

Employees

145

Website

parabilismed.com

IPO

2026-06-10

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)